3 days popular7 days popular1 month popular3 months popular

Protein-based therapy shows promise against resistant leukemia

Resistance of cells to contemporary chemotherapy is one of the most formidable obstacles to treating (ALL), the most common form of childhood cancer. Now researchers at Children’s Hospital Los Angeles (CHLA) have designed and developed a new protein-based therapy they believe will prove highly effective against drug-resistant . It may also amplify the potency of standard treatment options such as chemotherapy and .

Cancer Cell Death
Binding of the protein (green) to the surface of leukemia cells results in cell death via destruction of the cell’s nucleus (dark red) into pieces.
Credit:The Saban Research Institute of Children’s Hospital Los Angeles


Recombinant human CD19L-sTRAIL effectively targets B cell precursor acute lymphoblastic leukemia J Clin Invest. doi:10.1172/JCI76610. Additional contributors include Dorothea E. Myers, Zahide Ozer, Osmond J. D’Cruz and Hong Ma of the Children’s Center for Cancer and Blood Diseases and Children’s Hospital Los Angeles; Sanjive Qazi of CHLA and Gustavus Adolphus College, St. Paul, MN; and Rebecca Rose of Rose Pathology Services, St. Paul. The project was supported by a 2011 V-Foundation Translational Research Award and in part by DHHS grants R21-CA-164098, U01-CA-151837 and R01-CA-154471from the National Cancer Institute, part of the National Institutes of Health.

Children’s Hospital Los Angeles